AstraZeneca has signed a 555 million dollar agreement with Algen for the development of therapies based on Crispr technology, specialized in artificial intelligence.

The agreement with Algen Biotechnologies allows AstraZeneca to develop and commercialize therapies using Crispr genetic editing. Algen will receive 555 million dollars for achieving regulatory and commercial milestones in collaboration with AstraZeneca, without giving up equity stakes. Although AI promises to streamline the drug discovery process, few treatments developed with its help have reached advanced stages of clinical trials. AstraZeneca collaborates with Algen on immune system diseases, combining AI with Crispr for innovative solutions.